ERBB2 and breast carcinoma: In HER2-expressing cancer cells, compared with trastuzumab, tribody[(HER-2) 2xcd16] was better at inducing γδ T-cell- and NK-cell-mediated lysis, including pancreatic ductal adenocarcinoma (PDAC), breast cancer and EOC (117).